Since I’ve just spend close to a half-hour flipping through Big Pharma proxy filings, I figured I’d take just a little longer and put together a quick table of the best-paid chief executives in pharma and biotech. Enjoy.

The following data is all taken from 2007 proxy statements issued by the industry’s largest U.S. companies; I’ve linked to the proxies in the following list. (I’d have included European pharmas as well, but they don’t appear to file proxies in the U.S.)

1. Miles White, Abbott Laboratories: $33.3 million (proxy)
2. William Weldon, Johnson & Johnson: $31.9 million (proxy)
3. Fred Hassan, Schering-Plough: $30.3 million (proxy)
4. Kevin Sharer, Amgen: $19.9 million (proxy)
5. Richard Clark, Merck: $19.9 million (proxy)
6. Arthur Levinson, Genentech: $18.2 million (proxy)
7. Henri Termeer, Genzyme: $14.6 million (proxy)
8. Sidney Taurel, Eli Lilly: $13.0 million (proxy)
9. Bernard Poussot, Wyeth: $12.7 million (proxy)
10. James Cornelius, Bristol-Myers Squibb: $11.3 million (proxy)
11. John Martin, Gilead Sciences: $10.8 million (proxy)
12. Jeffrey Kindler, Pfizer: $9.5 million (proxy)
13. James Mullen, Biogen Idec: $9.0 million (proxy)

(Image by Flickr user velo_city, CC 2.0)